Yanan Zhu is ranked #1061 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Yanan Zhu (Wells Fargo) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Yanan Zhu's stock ratings?

About 69% of Yanan's ratings were profitable over a one-year hold, with an average return of +13.1% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Yanan Zhu

Yanan Zhu

Wells Fargo

Wall Street Analyst

★★★☆☆

#1061

on 13Foresight · ranked by our own returns

72%

Success Rate

+14.2%

Average Return

21 of 29 calls profitable · +2.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 72% of Yanan Zhu's ratings turned a profit when each position was held for 2 year — averaging +14.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

85 Buy 24 Hold 0 Sell

Yanan's Stock Coverage 27 ratings · 2026-07-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
SGMOQ Sangamo Therapeutics	Jun 25, 2026	HOLD	Buy +11775.2% avg upside 16 analysts	—	·
IONS Ionis Pharmaceuticals	Jun 25, 2026	BUY	Strong Buy +39.5% avg upside 43 analysts	$100.00 76.30% Upside	-25.6%
ENGN enGene Holdings	Jun 15, 2026	HOLD	Buy +427.8% avg upside 13 analysts	$2.00 7.59% Upside	+5.1%
BEAM Beam Therapeutics	Jun 04, 2026	BUY	Strong Buy +63.7% avg upside 25 analysts	$70.00 125.80% Upside	+12.3%
NTLA Intellia Therapeutics	May 12, 2026	HOLD	Buy +193.2% avg upside 37 analysts	$15.00 15.31% Upside	+1.6%
MGX Metagenomi, Inc.	May 11, 2026	BUY	Strong Buy +607.3% avg upside 8 analysts	$9.00 581.75% Upside	-2.2%
SRPT Sarepta Therapeutics	May 07, 2026	BUY	Buy +216.9% avg upside 49 analysts	$38.00 101.91% Upside	-8.9%
ONC BeOne Medicines	May 07, 2026	BUY	Strong Buy +16.1% avg upside 28 analysts	$400.00 31.59% Upside	-5.8%
CYTK Cytokinetics	May 07, 2026	BUY	Strong Buy +6.2% avg upside 36 analysts	$105.00 27.67% Upside	+14.2%
CRSP Crispr Therapeutics AG	May 05, 2026	HOLD	Buy +46.6% avg upside 41 analysts	$75.00 48.10% Upside	+1.8%
SYRE Spyre Therapeutics	Apr 14, 2026	BUY	Strong Buy -15.5% avg upside 23 analysts	$90.00 4.01% Downside	+52.7%
NAMS NewAmsterdam Pharma Company	Apr 02, 2026	BUY	Strong Buy +38.0% avg upside 18 analysts	$45.00 35.28% Upside	+6.9%
TSHA Taysha Gene Therapies	Mar 20, 2026	BUY	Strong Buy +138.9% avg upside 21 analysts	$11.00 104.56% Upside	+44.1%
RNA Atrium Therapeutics, Inc.	Mar 11, 2026	BUY	Strong Buy +180.3% avg upside 4 analysts	$25.00 104.54% Upside	-17.4%
EDIT Editas Medicine	Mar 10, 2026	HOLD	Buy +329.5% avg upside 33 analysts	$4.00 26.61% Upside	+39.0%
QURE uniQure	Mar 09, 2026	BUY	Strong Buy +43.1% avg upside 29 analysts	$60.00 46.06% Upside	+151.1%
ARCT Arcturus Therapeutics	Mar 04, 2026	BUY	Buy +330.3% avg upside 36 analysts	$20.00 198.03% Upside	+10.8%
IOVA Iovance Biotherapeutics	Feb 25, 2026	BUY	Strong Buy +211.6% avg upside 24 analysts	$14.00 246.58% Upside	+10.4%
AUTL Autolus Therapeutics	Jan 14, 2026	BUY	Strong Buy +600.4% avg upside 16 analysts	$5.00 237.76% Upside	+2.1%
CLLS Cellectis SA	Jan 13, 2026	HOLD	Strong Buy +586.9% avg upside 16 analysts	$4.00 37.96% Upside	-17.6%
FATE Fate Therapeutics	Jan 05, 2026	HOLD	Strong Buy +283.8% avg upside 31 analysts	$2.50 17.31% Downside	+190.1%
ADAPY Adaptimmune Therapeutics	May 14, 2025	HOLD	Hold +7236.9% avg upside 10 analysts	$1.00 3523.25% Upside	·
AFMDQ Affimed	May 14, 2025	HOLD	Buy +12648900.0% avg upside 15 analysts	$0.10 99899.98% Upside	·
VYGR Voyager Therapeutics	May 06, 2025	BUY	Strong Buy +336.0% avg upside 23 analysts	$10.00 208.60% Upside	+1.5%
TECX Tectonic Therapeutic	May 16, 2024	HOLD	Strong Buy +64.1% avg upside 24 analysts	—	+67.2%
TCRT Alaunos Therapeutics	Aug 16, 2023	HOLD	Buy +632.3% avg upside 13 analysts	$30.00 1339.59% Upside	-90.6%
ARGX Argenx Se	Feb 02, 2021	HOLD	Strong Buy -14.1% avg upside 46 analysts	$326.00 62.72% Downside	+14.7%

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Yanan Zhu — Frequently Asked Questions

How accurate are Yanan Zhu's stock ratings?

Based on the calls 13Foresight could measure, about 69% of Yanan's ratings were profitable over a one-year hold, with an average return of +13.1% per rating, or +2.8% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Yanan ranked on 13Foresight?

Yanan Zhu is currently ranked #1061 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Yanan cover?

Yanan most recently has ratings on SGMOQ, IONS, ENGN, BEAM, NTLA, MGX, SRPT, ONC, CYTK, CRSP, SYRE, NAMS and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!